THE DEAL, AT A GLANCE
From the announcementTriveni
01Who is involvedBacked by the University of Warwick, she currently reports on the latest in the partnering, investment space, as well as drug modalitiesFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedTriveni raised $65M Series C, announced 2026-06-22From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersTriveni’s $65m Series C supports advancement of TRIV-573, a bispecific eczema candidate targeting both skin barrier breakdown and Th2 inflammation pathways.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Triveni · Financing Record
Explore source-linked visual explanations for Triveni. Unsupported claims are withheld while source review continues.
Record 6499 · Recorded date: 2026-06-22
Explore company records →